[Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
As advances in new therapeutic modalities are urgently needed, one of which is tumor-specific immunotherapy. We identified an HLA-A24-restricted antigenic peptide, survivin-2B80-88, and started a phase I clinical study of survivin-2B peptide vaccination in patients with advanced or recurrent colorectal cancer. Of 15 patients who finished receiving the vaccination schedule, three suffered slight toxicities. In 6 patients, tumor marker levels decreased transiently during the period of vaccination. Slight reduction in tumor volume was observed in one patient, which was considered a minor responder. Analysis of peripheral blood lymphocytes of one patient using HLA-A24/peptide tetramers revealed an increase in peptide-specific CTL after vaccination. This phase I clinical study revealed that administration of the survivin-2B peptide is safe. The vaccination with survivin-2B peptide alone was not enough to elicit clinical responses. Consequently, we have recently started the second clinical study of survivin-2B peptide vaccine in combination with various adjuvants.
Tsuruma
Tetsuhiro
T
Dept. of Surgery, Sapporo Medical University School of Medicine.
Torigoe
Toshihiko
T
Hata
Fumitake
F
Furuhata
Tomohisa
T
Sato
Noriyuki
N
Hirata
Koichi
K
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D019496:Cancer Vaccines / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000009:adverse effects / Q000276:immunology*; D008875:Middle Aged; D009363:Neoplasm Proteins; D000077022:Survivin; D016896:Treatment Outcome; D014611:Vaccination
C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin